Dr Roberto Iacovelli brings you his interpretation of the data when deciding upon the best approach to treatment sequencing in mRCC.
Dr Roberto Iacovelli brings you his interpretation of the data when deciding upon the best approach to treatment sequencing in mRCC.
Dr Roberto Iacovelli studied medicine at the “Sapienza” University of Rome, Italy. At the same University, he specialized in medical oncology and had the PhD in molecular medicine and human pathology. He has international experience as a fellow at the Institute Gustave Roussy in France and as an oncologist in main referral oncological centres in Italy. Currently, he is a medical oncologist at the University Hospital of Verona, Italy. His research activities focus on metastatic renal cell carcinoma, prostate, and bladder cancer. His major interest is in predictive and prognostic factors in GU cancers as well as the sequence of therapy in renal cancer. He has published more than one hundred papers in international peer-reviewed journals and several abstracts at international conferences on these topics. Dr Iacovelli has received many national and international awards, such as the ASCO Cancer Foundation Merit Award in 2011 and the best poster award at the ESMO congress in 2012.
Astellas, Ipsen, Janssen, Merck, Pfizer and Sanofi.
Two emerging and two established targets
Announcing the publication of survey results
An expert overview of the EMERALD subgroup analysis
Managing patients with nccRCC: guidelines, recommendations, and best practice
Risk factors, diagnostic tools and treatment options for different patient groups
Exploring emerging treatment strategies presented at SABCS 2024